Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 9/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749741 | 0.83 | RPS6KB1 (0.40) | RPS6KB1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1749516 | 0.80 | NOTUM (0.40) | RPS6KB1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL17612866 | 0.78 | NOTUM (0.61) | KEAP1NFE2L2NOTUM | |
| SCHEMBL24811432 | 0.78 | NOTUM (0.61) | KEAP1NFE2L2NOTUM | |
| SCHEMBL17599441 | 0.78 | NOTUM (0.61) | KEAP1NFE2L2NOTUM | |
| SCHEMBL1749401 | 0.78 | MAPT (0.46) | RPS6KB1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1749815 | 0.78 | GAA (0.40) | RPS6KB1ALDH1A1MAPTTDP1NOTUM | |
| SCHEMBL1749277 | 0.77 | CHRM4 (0.40) | RPS6KB1KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1749215 | 0.77 | ALDH1A1 (0.44) | RPS6KB1ALDH1A1MAPTTDP1NOTUM | |
| SCHEMBL1749230 | 0.77 | RPS6KB1 (0.39) | RPS6KB1KDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | RPS6KB1 3306/4885KDM4E 2966/4885ALDH1A1 286/4885 |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | RPS6KB1 3742/4885KDM4E 2896/4885ALDH1A1 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.